Functions of Heat Shock Proteins in Pathways of the Innate and Adaptive Immune System
References Subscriptions Permissions Email Alerts
Robert Julian Binder J Immunol 2014; 193:5765-5771; ; doi: 10.4049/jimmunol.1401417 http://www.jimmunol.org/content/193/12/5765
This article cites 105 articles, 53 of which you can access for free at: http://www.jimmunol.org/content/193/12/5765.full#ref-list-1 Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscriptions Submit copyright permission requests at: http://www.aai.org/ji/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/cgi/alerts/etoc
The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 9650 Rockville Pike, Bethesda, MD 20814-3994. Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
This information is current as of December 8, 2014.
Brief Reviews
The
Journal of
Immunology
Functions of Heat Shock Proteins in Pathways of the Innate and Adaptive Immune System Robert Julian Binder
H
eat shock proteins (HSPs) were inadvertently discovered in 1962 when Drosophila salivary glands were grown overnight at elevated temperatures and were found to be highly upregulated (1). Several HSPs have been discovered since then, and they are grouped into families based on m.w. (e.g., hsp10, hsp40, hsp60, hsp70, hsp90), although family members may be structurally unrelated (2). The ability of HSPs to chaperone nascent polypeptides for proper folding and expression is their best known function (2); however, a significant role for HSPs in the immune system has emerged in the past three decades and is the focus of this review. The usefulness of HSP-mediated immune responses for immunotherapy of disease is mentioned. The immunological roles for HSPs, in situ or in the extracellular environment, rely fully or partially on the fundamental property of a select few HSPs to act as a chaperone of peptides, in addition to whole proteins. Peptide-binding properties of select HSPs
The intracellular association of HSPs with peptides has been demonstrated on structural, biochemical, and immunological levels. The bacterial homolog of mammalian hsp70, DnaK, was crystallized in 1996, together with its associated peptide occupying a peptide-binding groove (3, 4). Peptide binding sites have been identified for calreticulin (5) and hsp90 (6), as well as its endoplasmic reticulum (ER) paralogue gp96 (7). Peptides associate with each of these HSPs with low affinity Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261 Received for publication June 3, 2014. Accepted for publication September 7, 2014. This work was supported by National Institutes of Health Grants CA90440, CA137133, and AI079057. Address correspondence and reprint requests to Dr. Robert Julian Binder, University of Pittsburgh School of Medicine, E1058 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15261. E-mail address: [email protected] www.jimmunol.org/cgi/doi/10.4049/jimmunol.1401417
and no or low specificity (8–10). The peptides are generally 10– 30 aa in length and are generated during normal protein turnover in cells (8–10). Because the peptide binding sites for each HSP are different, the case can be made for distinct associated peptide repertoires. It is important to note that the association of HSPs with peptides is not an artifact of cell lysis (11). In many immunological systems tested, peptides derived from antigenic proteins were shown to be associated with cytosolic (hsp90 and hsp70) and ER (calreticulin and gp96) HSPs. These antigenic peptides include those derived from viral (12–18) or bacterial (19) proteins from infected cells, tumor Ags from malignant cells (20–22), model Ags from transfected cells (23–27), and alloantigens from MHC-mismatched cells (28, 29). Immunologically, peptides chaperoned by HSPs reflect the antigenic fingerprint of a cell. Finally, the association of HSPs with peptides appears to be an evolutionarily conserved property, because HSPs from bacteria (3), amphibians (30), rodents (12–14, 17–19, 21–25, 31), and primates (16, 20) can bind peptides. The HSPs and MHC are the two prominent families of peptide-binding proteins in immunology. In situ HSPs and the immune system
HSPs and the MHC class I Ag-presentation pathway. The classical
view of the pathway that leads to productive peptide presentation by MHC class I (MHC I) begins with protein degradation by the cytosolic proteasome. Although the source of proteasome substrates is under intense debate (32, 33), extended polypeptides are cleaved to small peptides with the correct C-termini, but extended N-termini, for occupying MHC I. For several years these peptides were inexplicably assumed to diffuse from the proteasome to the TAP for transportation into the ER (34). ER peptides are loaded onto nascent MHC H chains with the assistance of the peptide loading complex (PLC) comprising TAP, tapasin, ERp57, and calreticulin. During loading onto MHC I, peptides simultaneously undergo a final round of N-terminal trimming by ER-associated protease (34). Peptide-loaded MHC I H chains associate with b2M, and the trimeric complex is transported through the Golgi and ultimately expressed on the cell surface, where it can be recognized by T cells. Studies from several laboratories argue strongly for Abbreviations used in this article: DC, dendritic cell; ER, endoplasmic reticulum; HSP, heat shock protein; MHC I, MHC class I; PLC, peptide-loading complex; RA, rheumatoid arthritis; Treg, regulatory T cell. Copyright Ó 2014 by The American Association of Immunologists, Inc. 0022-1767/14/$16.00
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
For more than 50 years, heat shock proteins (HSPs) have been studied for their role in protecting cells from elevated temperature and other forms of stress. More recently, several roles have been ascribed to HSPs in the immune system. These include intracellular roles in Ag presentation and expression of innate receptors, as well as extracellular roles in tumor immunosurveillance and autoimmunity. Exogenously administered HSPs can elicit a variety of immune responses that have been used in immunotherapy of cancer, infectious diseases, and autoimmune disease. The Journal of Immunology, 2014, 193: 5765–5771.
5766
resultant peptides can be presented by MHC I, a process referred to as cross-presentation (34). There is debate regarding the cellular compartment in which Ags are processed for cross-presentation (34, 50). Vesicular bodies into which Ag is internalized, such as endosomes or phagosomes, may become specialized peptide-processing and MHC I–loading compartments through recruitment of selective ER proteins that perform these roles. MHC I–peptide complexes in these vesicles recycle to the cell surface (50). A prevalent second pathway involves trans-endosomal membrane transport of the Ag to the cytosol where it enters the classical MHC I Ag-presentation pathway (34). In support of this, the proteasome dependence for cross-presentation of Ags by APCs was shown (34). hsp90 and hsp70 are intimately involved in the extrusion of Ags from the endosomes to the cytosol through a putative pore structure (51, 52). This mechanism involves the unfolding and linearization of the protein Ags by hsp90 prior to extrusion. Pharmacological inhibition of hsp90 or its deletion in cross-presenting APCs or Ag rendered structurally inflexible through fixation abrogated Ag cross-presentation (51). Interestingly, hsp70 was shown to negatively regulate Ag extrusion, arguing for cooperative regulation of this process by two cytosolic HSPs. These specific roles for hsp70 and hsp90 may account, at least in part, for the extraordinary efficiency of extracellular HSPs at cross-presenting Ags that are chaperoned by them (as described below). Endogenous HSPs, through functionality or expression levels, appear to be key regulators of Ag cross-presentation. Coincidentally, hsp90 and hsp70 are induced in response to stress and IFNs, the precise situations during which cross-presentation is required. gp96 as a chaperone of innate immune receptors. gp96 has a welldescribed function in the ER for folding nascent polypeptides into their final conformation (2). These client proteins are wholly dependent on gp96 for proper expression. All TLRs, with the exception of TLR3, are client proteins of gp96 (53). Folding of TLRs is dependent on dimerization of gp96 and its cochaperone CNPY3 also present in the ER lumen. Following gp96 depletion in APCs, TLRs are rapidly removed from the cell surface and intracellular vesicles, rendering APCs functionally unresponsive to corresponding TLR ligands, as measured by a lack of NF-kB activation and secretion of cytokines. Structural studies on gp96 identified the TLRbinding domains, which are distinct from ATP-binding domains (54). Several other client proteins, such as a and b integrins, known for their roles in influencing immune responses, bind to the same domain. Thus, mice deficient in gp96 expression are severely susceptible to bacterial infection (55). TLRs are the critical sensors for recognition of microorganisms, and their expression patterns are closely related to function. Upstream processes that determine TLR expression are expected to regulate immunity to pathogens; thus, gp96 is a master chaperone that can control immune responses with fine specificity based on selectivity and titratability in client binding. Extracellular HSPs and influence of adaptive immunity
Collectively, HSPs are the most abundant proteins in cells, and their liberation into the extracellular environment is a key immunological indicator of loss of cellular integrity. HSPs in the extracellular environment are a product of pathologic cell
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
modifications to this oversimplistic classical pathway. First, hydrophobic amino acids present in short peptides (which cannot assume higher-ordered structures) cannot exist in the aqueous intracellular environment without being shielded (35), a role provided by HSPs (Fig. 1). Second, diffusion as a transport mechanism is too uneconomical to satisfy the calculated efficiency of production of peptide/MHC I on the cell surface (36, 37). This efficient process can be satisfied by factoring in the HSPs. hsp70, hsp90, gp96, and calreticulin were proposed, in 1994, to form a relay line for efficient transport of peptides from the proteasome to MHC I (38). The following evidence strongly supports this proposal. 1) Disruption of peptide binding to hsp70 or hsp90 with deoxyspergualin or tanespimycin, respectively, abrogates peptide presentation by MHC I (39, 40). Knock down of hsp90a with small interfering RNA produces a similar phenotype (41). 2) When peptides are eluted from highly purified, apparently homogenous HSPs, MHC-binding peptides and their precursors (intermediates of the processing events) are found (8–10, 12–29). 3) Transfer of progressively trimmed peptides between HSPs and MHC I has been observed in the ER (42). 4) Naturally occurring free peptides cannot be detected in cells even after the most rigorous of experimental exploration (11). Once cells or their derived lysates are treated with ATP or mild acid, agents known to release peptides from chaperones, peptides can be readily detected (11). 5) Peptides transported by TAP associate with gp96 and other ER chaperones, including protein disulfide isomerase (43). These HSPs adhere to certain specifications to satisfactorily transfer peptides for MHC I presentation. The ubiquitous expression of hsp70, hsp90, calreticulin, and gp96 in cells essentially ensures that the MHC I–presentation pathway remains functional in all nucleated cells. IFN-g inducibility of a majority of the components of the MHC I–presentation pathway also applies to HSPs involved in the pathway (44, 45). The receipt and delivery of peptides by HSPs suggest a physical association of those HSPs with other components of the pathway. hsp90 was shown to physically associate with the proteasome and, in certain instances, replace the PA28 subunits (46, 47), situating hsp90 in an optimal position to receive peptides being generated by the proteasome. hsp70 and hsp90 form heteromultimeric complexes in the cytosol with other cochaperones (48). Although this complex is essential for client protein–refolding roles, peptide transfer within this complex has yet to be tested. hsp70 also were shown to be in physical proximity to TAP (49), an association that would allow delivery of HSP-chaperoned peptides to TAP for onward translocation into the ER. This suggests that the proteasomes, hsp70, hsp90, and TAP could exist as a single cytosolic multimeric unit akin to the PLC. Within the ER, the PLC has been well defined, with calreticulin playing a peptide-binding role. The transfer of peptides among calreticulin, gp96, and MHC I in the ER has been documented (42). The apparent lack of association of gp96 (and ERassociated protease) with other PLC members may reflect a weaker or transient interaction with this complex, considering the other significant roles for gp96 in ER biology. Other unidentified chaperones may be involved in this pathway. Cytosolic HSPs in endosome–cytosol trafficking of cross-presented Ags. APCs capture Ags from the extracellular space and internalize them into vesicular bodies. Following processing of the Ags,
BRIEF REVIEWS: HSPs IN THE IMMUNE SYSTEM
The Journal of Immunology
5767
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
FIGURE 1. (AA) hsp90 and hsp70 are intricately involved in shuttling peptides from the proteasome to TAP in the cytosol. In the ER, gp96 and calreticulin (CRT) sequentially transfer peptides from TAP to MHC. (AB) hsp90 and hsp70 regulate the extrusion of Ags from endosomes to the cytosol through a putative pore during Ag cross-presentation. (AC) gp96 folds and controls the expression of TLRs and other client proteins. HSPs released from tumor cells through a variety of mechanisms (BA) are endocytosed by CD91 expressed on APCs (BB). HSPs and the chaperoned peptides are processed within the cell (BC) before presentation of the peptide on MHC molecules to CD4 or CD8 T cells (BD). (BE) CD91 also serves as a signaling receptor, controlling the expression of cytokines and costimulatory molecules. (BF) Thus, HSPs can prime diverse Th cell responses.
5768
1) Tumor Ags have been grouped into neoantigens resulting from mutated, overexpressed, or abnormally expressed proteins (67), although the former are ubiquitous and appear to be the most immunogenic (67). Priming of tumor-specific T cells requires that these tumor Ags are transferred from the Ag-expressing (tumor) cell to APCs for cross-presentation (68). Mutated self proteins, expressed by a few abnormal cells, set the limitations for the amount of material available for cross-presentation during tumorigenesis. These limits have been quantified and are in the picogram range (69, 70). However, cross-presentation of soluble protein Ags, as measured in several model Ag and pathogen experimental systems, requires ∼10 to hundreds of micrograms [e.g., (66, 71)]. The five orders of disparity between these two quantities are satisfied when HSP– peptide complexes are considered as the mediators of Ag transfer (69). Peptides chaperoned by HSPs are efficiently cross-presented by APCs, and the efficiency is largely attributed to the presence of an endocytic receptor CD91 (60–62, 72). The mechanisms associated with cross-presentation of HSP-chaperoned peptides have been quantified and detailed in a large body of work (60–63, 73). Importantly, femtogram to picogram levels of a specific peptide complexed to 10 mg of gp96, hsp70, or calreticulin are sufficient for cross-presentation (74). My group proposed that the HSP–peptide–CD91
mode of Ag transfer must be used during tumorigenesis given limiting Ag levels. Mice deficient in CD91 expression on APCs failed to mount immune responses to growing tumors (75), a phenotype previously seen in IFN-g– or rag-deficient mice (64). CD91-deficient mice or tumors expressing endogenous inhibitors of CD91 fail to adequately cross-present Ag and stimulate T cell responses. These observations point to an indispensable role for endogenous tumor-derived HSPs and their receptor CD91 in establishing immune responses to a developing tumor. In other pathological situations in which Ag load is considerably higher, other modes of Ag transfer may apply (76). 2) Tumors, being of self origin, lack expression of pathogenassociated molecular patterns, which typically elicit costimulation. We do not know the origin of costimulation during tumorigenesis. Purified gp96, hsp70, and calreticulin were shown to stimulate and mature APCs, which are associated with cytokine release and upregulation of costimulatory molecules (77, 78). HSPstimulated dendritic cells (DCs) are perfectly suited for priming T cells. Incidentally, CD91 was shown to be a signaling receptor for immunogenic HSPs activating p38 MAPK and NF-kB (78). The repertoire of cytokines released and costimulatory molecules expressed are specific to the CD91+ APC and the HSP used, but routinely includes IL-1b, TNF-a, IL-6, IL12, and GM-CSF (78). HSP-stimulated APCs upregulate CD80, CD86, CD40, and MHC class II (77). In a tumor microenvironment, with the release of multiple HSPs and with APCs in this locale, the response is of the Th1 type, capable of rejecting the tumor. As a single entity, the HSP–peptide complexes are capable of priming T cell responses. These responses are considered in juxtaposition with other intracellular molecules capable of stimulating APCs, such as HMGB1, dsDNA, and uric acid (79). Cellular necrosis, which is a near-universal occurrence in cancer, appears to be the most rational mechanism for extracellular HSP release (56). However, there are other mechanisms through which HSPs are accessible to their receptor(s) on immune cells (57–59, 80). Therefore, immunologically dangerous situations can be classified quantitatively and qualitatively according to the potential for release of HSPs, or more generally, intracellular content, which provide signals that may complement, supersede, or antagonize those originating from other pathways (e.g., pathogen-associated molecular pattern–pattern recognition receptor) or, in the absence of other apparent signals, elicit exclusive responses. Extracellular HSPs and etiology of autoimmunity. During homeostasis, it is necessary that HSPs are largely inaccessible to their receptors. Sustained release of HSPs into the extracellular environment would be expected to trigger autoimmunity based on the observed proinflammatory conditions elicited by some HSPs. Although there is no formal experimental demonstration of this expectation, there is some suggestion of it in various pathological conditions.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
death, abnormal active secretory mechanisms, or nonconventional cellular expression on the membrane (56–59). A select group of HSPs, when extracellular, is recognized by cellular immune sentinels. Such recognition allows HSPs to be critical mediators of immune responses, initiating specific immune responses against cancers or pathogen-infected cells, exacerbating pre-existing inflammatory conditions, or suppressing ongoing immunity. The surprising discovery of HSP receptors on APCs afforded a molecular description of these immunological mechanisms (60–63) (Fig. 1B). Extracellular HSPs are necessary for immunosurveillance of cancer. The ability of the immune system to recognize aberrant, premalignant cells and eliminate them before they become pathological is the hallmark of tumor immunosurveillance (64). Immunosurveillance and resulting immunoediting include an elimination, equilibrium, and escape phase (64). T cell responses, initiated during the elimination phase, are primarily responsible for rejection of the tumorigenic cells (65). T cells receive signal 1 through TCR recognition of Ag presented by MHC. Recognition of costimulatory ligands on APCs by corresponding receptors on T cells provides signal 2. These signals are provided in the context of a cytokine milieu. In a majority of cases, these signals are sufficient for T cell priming, and all abnormal premalignant cells are eliminated. A failure of the immune system to completely eliminate the abnormal cells sets the stage for an equilibrium phase, a state that can persist for many years. Cancers then develop when they escape immune control. The conventional mechanism of priming T cells has been largely elucidated using experimental systems with model Ags or pathogens (66). These mechanisms are not wholly applicable during tumorigenesis and have been revised to include the immunological effects of HSPs for two reasons.
BRIEF REVIEWS: HSPs IN THE IMMUNE SYSTEM
The Journal of Immunology
hsp70 (see Ref. 102)], in patients with autoimmune diabetes [with hsp60 (95, 103)], and in virally infected patients [with hsp70 (104)]. The plasticity of HSP-mediated immunity (i.e., priming Th1, Th2, Th17, and/or Tregs) depends on the ability of HSPs to engage local APCs through cell surface receptors, thereby stimulating diverse costimulatory signals (77, 78, 95). CD91 is one such prominent receptor. When HSPs are introduced at higher doses, we speculate that additional APCs and/or (lower-affinity) cell surface receptors (63) could be targeted. The 24mer peptide of hsp60 offers a clear example: it was shown to bind TLR2 and TLR4 mediating anti- and proinflammatory conditions, respectively (95). The repertoires of cytokines released by bone marrow–derived dendritic cells, peritoneal exudate cells, and lymph node DCs stimulated with HSPs are overlapping, but distinct, and dependent on receptor usage (78). The overall signal received by the cell from engagement of multiple signaling receptors, as well as the resulting costimulation, determines the Th cell response that is primed. The recent demonstration that blocking Treg generation allowed gp96 to mediate stronger peptide-specific CTL responses in BALB/c mice provides further evidence for this dynamic interplay, as do the studies on hsp60 (95). Although many of the experimental systems are necessarily minimalistic, it is important to consider the sum of these signals during pathology in conjunction with signals emanating from other engaged (pattern recognition) receptors.
Conclusions
It has been 30 years since Srivastava and colleagues first described the immunogenicity of HSPs. The HSPs (and the receptor CD91) are evolutionarily ancient; thus, it is unsurprising that the immune system has evolved to use HSPs in conserved pathways. As we continue to better understand their functions, other roles for HSPs in innate and adaptive immunity may be uncovered, not only in the diseased state but also during homeostasis. With the recent appreciation of various commensals in regulating immune responses, for example, we are yet to appreciate the role of commensal-derived HSPs in generating signals that may affect those emanating from PRRs.
Acknowledgments I thank Drs. Abigail Sedlacek and Yu Jerry Zhou for advice and discussions.
Disclosures R.J.B. is a named inventor of intellectual property that is being evaluated under his National Institutes of Health grants, and the technology has been licensed to a company in which R.J.B. has no ownership interest or consulting contract and from which he has no sponsored research agreements. His significant financial interest consists only of a share of license fees and possible future royalties from the commercialization of his invention.
References 1. Ritossa, F. 1962. A new puffing pattern induced by temperature shock and DNP in drosophila. Experientia 18: 571–573. 2. Lindquist, S., and E. A. Craig. 1988. The heat-shock proteins. Annu. Rev. Genet. 22: 631–677. 3. Zhu, X., X. Zhao, W. F. Burkholder, A. Gragerov, C. M. Ogata, M. E. Gottesman, and W. A. Hendrickson. 1996. Structural analysis of substrate binding by the molecular chaperone DnaK. Science 272: 1606–1614. 4. Peng, P., A. Me´noret, and P. K. Srivastava. 1997. Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. J. Immunol. Methods 204: 13–21.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
The etiology of rheumatoid arthritis (RA) remains largely unresolved and is likely to be a combination of genetic, environmental, and immunological factors. However, a case can be made for extracellular HSPs as a factor contributing to the initiation and/or progression of RA. Elevated levels of hsp70 and gp96 are observed in synovial fluids and fibroblasts from inflamed joints of RA patients (81–83). This increase is not observed in nonarthritic joints of the same patient. Macrophages lining the synovial tissue of RA joints are highly responsive to extracellular HSPs and produce cytokines, including IL-1b, IL-6, and TNF-a, which exacerbate the inflammatory conditions (83). Already, therapy targeting HSPs with Abs is being envisaged. A therapeutic focus on the upstream molecules that initiate inflammation is expected to be more successful than the current anti–TNF-a therapy. A majority of the peptides chaperoned by HSPs are self peptides. In the event that autoreactive T cells are not thymically deleted, they can be primed following HSP-mediated crosspresentation of these self peptides (84), further contributing to cellular destruction of arthritic joints. In some other instances, these self peptides may even be derived from the HSP molecule itself and, thus, are a target for cellular immunity or are able to induce protective immunity (85–87). In experimental systems, transgenic mice with enforced cell surface expression of gp96 develop spontaneous lupus-like autoimmune disease as a result of chronic stimulation of DCs (88). Although there were no apparent gross abnormalities, these mice displayed severe glomerulonephritis by 20 wk of age. DCs in these mice were found to be hyperactive and capable of priming self-reactive T cells, and of breaking down peripheral tolerance. These studies were able to demonstrate the direct proinflammatory properties of constitutive extracellular gp96 in mice, a condition similar to immunization with tumor cells secreting HSPs (89). Exogenously administered HSPs and modulation of immune responses. Immunogenicity of HSPs was first shown in 1986 during a search of the immunogenic entity of tumor cells (90). Srivastava et al. biochemically fractionated tumor cells and tested each fraction for its ability to elicit tumor rejection in mice. Apparently homogenous preparations of gp96 were shown to do so. Thus, when mice are immunized with gp96 isolated from a tumor, they become resistant to a subsequent challenge of that specific tumor. The specificity of the immune responses was against peptides chaperoned by gp96. These observations are true for other peptide-chaperoning HSPs, including hsp70 (91, 92), hsp90 (91), calreticulin (93), hsp110 (94), and grp170 (94), and are effective in many disease models in rodents (90–94), frogs (30), and humans (see below). Following on those pioneering studies, depending on the dose and experimental setting, HSPs were shown to prime not only specific antitumor immunity (90–94), but also regulatory T cell (Treg) responses [hsp70 (85), hsp60 (95, 96), gp96 (97–99)], Ab responses [hsp60 (95), gp96 (13)], or Th17 responses (78) (calreticulin, gp96). The natural extension of these observations was therapeutic experimentation in various diseases. First, in rodent models, HSPs were shown to regress established tumors and prevent metastasis [gp96 (100), hsp70 (100), hsp110 (94), grp170 (94)], prevent or delay autoimmunity [hsp60 (95), gp96 (97–99)], and reduce pathogen load [gp96 (13, 18, 101)]. There is an extensive list of clinical trials in patients with a variety of cancers [with gp96,
5769
5770
32. Yewdell, J. W., and C. V. Nicchitta. 2006. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol. 27: 368–373. 33. Rock, K. L., D. J. Farfa´n-Arribas, J. D. Colbert, and A. L. Goldberg. 2014. Reexamining class-I presentation and the DRiP hypothesis. Trends Immunol. 35: 144–152. 34. Blum, J. S., P. A. Wearsch, and P. Cresswell. 2013. Pathways of antigen processing. Annu. Rev. Immunol. 31: 443–473. 35. Dick, T. P., T. Ruppert, M. Groettrup, P. M. Kloetzel, L. Kuehn, U. H. Koszinowski, S. Stevanovic´, H. Schild, and H. G. Rammensee. 1996. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86: 253–262. 36. Villanueva, M. S., P. Fischer, K. Feen, and E. G. Pamer. 1994. Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity 1: 479–489. 37. Yewdell, J. W., E. Reits, and J. Neefjes. 2003. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3: 952–961. 38. Srivastava, P. K., H. Udono, N. E. Blachere, and Z. Li. 1994. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39: 93–98. 39. Binder, R. J., N. E. Blachere, and P. K. Srivastava. 2001. Heat shock proteinchaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J. Biol. Chem. 276: 17163–17171. 40. Callahan, M. K., M. Garg, and P. K. Srivastava. 2008. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proc. Natl. Acad. Sci. USA 105: 1662–1667. 41. Kunisawa, J., and N. Shastri. 2006. Hsp90alpha chaperones large C-terminally extended proteolytic intermediates in the MHC class I antigen processing pathway. Immunity 24: 523–534. 42. Kropp, L. E., M. Garg, and R. J. Binder. 2010. Ovalbumin-derived precursor peptides are transferred sequentially from gp96 and calreticulin to MHC class I in the endoplasmic reticulum. J. Immunol. 184: 5619–5627. 43. Spee, P., and J. Neefjes. 1997. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur. J. Immunol. 27: 2441–2449. 44. Anderson, S. L., T. Shen, J. Lou, L. Xing, N. E. Blachere, P. K. Srivastava, and B. Y. Rubin. 1994. The endoplasmic reticular heat shock protein gp96 is transcriptionally upregulated in interferon-treated cells. J. Exp. Med. 180: 1565–1569. 45. Wang, S., M. Zhou, F. Lin, D. Liu, W. Hong, L. Lu, Y. Zhu, and A. Xu. 2014. Interferon-g induces senescence in normal human melanocytes. PLoS ONE 9: e93232. 46. Yamano, T., S. Mizukami, S. Murata, T. Chiba, K. Tanaka, and H. Udono. 2008. Hsp90-mediated assembly of the 26 S proteasome is involved in major histocompatibility complex class I antigen processing. J. Biol. Chem. 283: 28060– 28065. 47. Yamano, T., S. Murata, N. Shimbara, N. Tanaka, T. Chiba, K. Tanaka, K. Yui, and H. Udono. 2002. Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing. J. Exp. Med. 196: 185–196. 48. French, J. B., H. Zhao, S. An, S. Niessen, Y. Deng, B. F. Cravatt, and S. J. Benkovic. 2013. Hsp70/Hsp90 chaperone machinery is involved in the assembly of the purinosome. Proc. Natl. Acad. Sci. USA 110: 2528–2533. 49. Chen, D., and M. J. Androlewicz. 2001. Heat shock protein 70 moderately enhances peptide binding and transport by the transporter associated with antigen processing. Immunol. Lett. 75: 143–148. 50. Jutras, I., and M. Desjardins. 2005. Phagocytosis: at the crossroads of innate and adaptive immunity. Annu. Rev. Cell Dev. Biol. 21: 511–527. 51. Ichiyanagi, T., T. Imai, C. Kajiwara, S. Mizukami, A. Nakai, T. Nakayama, and H. Udono. 2010. Essential role of endogenous heat shock protein 90 of dendritic cells in antigen cross-presentation. J. Immunol. 185: 2693–2700. 52. Imai, T., Y. Kato, C. Kajiwara, S. Mizukami, I. Ishige, T. Ichiyanagi, M. Hikida, J. Y. Wang, and H. Udono. 2011. Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells. Proc. Natl. Acad. Sci. USA 108: 16363–16368. 53. Liu, B., Y. Yang, Z. Qiu, M. Staron, F. Hong, Y. Li, S. Wu, Y. Li, B. Hao, R. Bona, et al. 2010. Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone. Nat. Commun. 1: 79. 54. Wu, S., F. Hong, D. Gewirth, B. Guo, B. Liu, and Z. Li. 2012. The molecular chaperone gp96/GRP94 interacts with Toll-like receptors and integrins via its Cterminal hydrophobic domain. J. Biol. Chem. 287: 6735–6742. 55. Staron, M., Y. Yang, B. Liu, J. Li, Y. Shen, J. C. Zu´n˜iga-Pfl€ ucker, H. L. Aguila, I. Goldschneider, and Z. Li. 2010. gp96, an endoplasmic reticulum master chaperone for integrins and Toll-like receptors, selectively regulates early T and B lymphopoiesis. Blood 115: 2380–2390. 56. Miyake, Y., and S. Yamasaki. 2012. Sensing necrotic cells. Adv. Exp. Med. Biol. 738: 144–152. 57. Hunter, M. C., K. L. O’Hagan, A. Kenyon, K. C. Dhanani, E. Prinsloo, and A. L. Edkins. 2014. Hsp90 binds directly to fibronectin (FN) and inhibition reduces the extracellular fibronectin matrix in breast cancer cells. PLoS ONE 9: e86842. 58. Altmeyer, A., R. G. Maki, A. M. Feldweg, M. Heike, V. P. Protopopov, S. K. Masur, and P. K. Srivastava. 1996. Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. Int. J. Cancer 69: 340–349. 59. Becker, B., G. Multhoff, B. Farkas, P. J. Wild, M. Landthaler, W. Stolz, and T. Vogt. 2004. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp. Dermatol. 13: 27–32. 60. Binder, R. J., D. K. Han, and P. K. Srivastava. 2000. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1: 151–155.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
5. Chouquet, A., H. Paı¨dassi, W. L. Ling, P. Frachet, G. Houen, G. J. Arlaud, and C. Gaboriaud. 2011. X-ray structure of the human calreticulin globular domain reveals a peptide-binding area and suggests a multi-molecular mechanism. PLoS ONE 6: e17886. 6. Stirling, P. C., S. F. Bakhoum, A. B. Feigl, and M. R. Leroux. 2006. Convergent evolution of clamp-like binding sites in diverse chaperones. Nat. Struct. Mol. Biol. 13: 865–870. 7. Ostrovsky, O., C. A. Makarewich, E. L. Snapp, and Y. Argon. 2009. An essential role for ATP binding and hydrolysis in the chaperone activity of GRP94 in cells. Proc. Natl. Acad. Sci. USA 106: 11600–11605. 8. Grossmann, M. E., B. J. Madden, F. Gao, Y. P. Pang, J. E. Carpenter, D. McCormick, and C. Y. Young. 2004. Proteomics shows Hsp70 does not bind peptide sequences indiscriminately in vivo. Exp. Cell Res. 297: 108–117. 9. Demine, R., and P. Walden. 2005. Testing the role of gp96 as peptide chaperone in antigen processing. J. Biol. Chem. 280: 17573–17578. 10. Li, H. Z., C. W. Li, C. Y. Li, B. F. Zhang, L. T. Li, J. M. Li, J. N. Zheng, and J. W. Chang. 2013. Isolation and identification of renal cell carcinoma-derived peptides associated with GP96. Technol. Cancer Res. Treat. 12: 285–293. 11. Me´noret, A., P. Peng, and P. K. Srivastava. 1999. Association of peptides with heat shock protein gp96 occurs in vivo and not after cell lysis. Biochem. Biophys. Res. Commun. 262: 813–818. 12. Nieland, T. J., M. C. Tan, M. Monne-van Muijen, F. Koning, A. M. Kruisbeek, and G. M. van Bleek. 1996. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc. Natl. Acad. Sci. USA 93: 6135–6139. 13. Navaratnam, M., M. S. Deshpande, M. J. Hariharan, D. S. Zatechka, Jr., and S. Srikumaran. 2001. Heat shock protein-peptide complexes elicit cytotoxic Tlymphocyte and antibody responses specific for bovine herpesvirus 1. Vaccine 19: 1425–1434. 14. Meng, S. D., T. Gao, G. F. Gao, and P. Tien. 2001. HBV-specific peptide associated with heat-shock protein gp96. Lancet 357: 528–529. 15. Heikema, A., E. Agsteribbe, J. Wilschut, and A. Huckriede. 1997. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol. Lett. 57: 69–74. 16. Strbo, N., M. Vaccari, S. Pahwa, M. A. Kolber, M. N. Doster, E. Fisher, L. Gonzalez, D. Stablein, G. Franchini, and E. R. Podack. 2013. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J. Immunol. 190: 2495–2499. 17. Basta, S., R. Stoessel, M. Basler, M. van den Broek, and M. Groettrup. 2005. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J. Immunol. 175: 796–805. 18. Z€ ugel, U., A. M. Sponaas, J. Neckermann, B. Schoel, and S. H. Kaufmann. 2001. gp96-peptide vaccination of mice against intracellular bacteria. Infect. Immun. 69: 4164–4167. 19. Rapp, U. K., and S. H. Kaufmann. 2004. DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int. Immunol. 16: 597–605. 20. Castelli, C., A. M. Ciupitu, F. Rini, L. Rivoltini, A. Mazzocchi, R. Kiessling, and G. Parmiani. 2001. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 61: 222–227. 21. Ishii, T., H. Udono, T. Yamano, H. Ohta, A. Uenaka, T. Ono, A. Hizuta, N. Tanaka, P. K. Srivastava, and E. Nakayama. 1999. Isolation of MHC class Irestricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J. Immunol. 162: 1303–1309. 22. Qian, J., S. Wang, J. Yang, J. Xie, P. Lin, M. E. Freeman, III, and Q. Yi. 2005. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin. Cancer Res. 11: 8808–8815. 23. Breloer, M., T. Marti, B. Fleischer, and A. von Bonin. 1998. Isolation of processed, H-2Kb-binding ovalbumin-derived peptides associated with the stress proteins HSP70 and gp96. Eur. J. Immunol. 28: 1016–1021. 24. Arnold, D., C. Wahl, S. Faath, H.-G. Rammensee, and H. Schild. 1997. Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein gp96. J. Exp. Med. 186: 461–466. 25. Binder, R. J., J. B. Kelly, III, R. E. Vatner, and P. K. Srivastava. 2007. Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins. J. Immunol. 179: 7254–7261. 26. Dai, J., B. Liu, M. M. Caudill, H. Zheng, Y. Qiao, E. R. Podack, and Z. Li. 2003. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immun. 3: 1. 27. Nair, S., P. A. Wearsch, D. A. Mitchell, J. J. Wassenberg, E. Gilboa, and C. V. Nicchitta. 1999. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J. Immunol. 162: 6426–6432. 28. Arnold, D., S. Faath, H. Rammensee, and H. Schild. 1995. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182: 885–889. 29. Lammert, E., D. Arnold, H. G. Rammensee, and H. Schild. 1996. Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation. Eur. J. Immunol. 26: 875–879. 30. Robert, J., T. Ramanayake, G. D. Maniero, H. Morales, and A. S. Chida. 2008. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J. Immunol. 180: 3176–3182. 31. Yedavelli, S. P., L. Guo, M. E. Daou, P. K. Srivastava, A. Mittelman, and R. K. Tiwari. 1999. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int. J. Mol. Med. 4: 243–248.
BRIEF REVIEWS: HSPs IN THE IMMUNE SYSTEM
The Journal of Immunology
85. van Herwijnen, M. J., L. Wieten, R. van der Zee, P. J. van Kooten, J. P. WagenaarHilbers, A. Hoek, I. den Braber, S. M. Anderton, M. Singh, H. D. Meiring, et al. 2012. Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis. Proc. Natl. Acad. Sci. USA 109: 14134–14139. 86. Massa, M., M. Passalia, S. M. Manzoni, R. Campanelli, L. Ciardelli, G. P. Yung, S. Kamphuis, A. Pistorio, V. Meli, A. Sette, et al. 2007. Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum. 56: 1648–1657. 87. Aalberse, J. A., B. J. Prakken, and B. Kapitein. 2012. HSP: Bystander Antigen in Atopic Diseases? Front. Immunol. 3: 139–144. 88. Liu, B., J. Dai, H. Zheng, D. Stoilova, S. Sun, and Z. Li. 2003. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc. Natl. Acad. Sci. USA 100: 15824–15829. 89. Strbo, N., K. Yamazaki, K. Lee, D. Rukavina, and E. R. Podack. 2002. Heat shock fusion protein gp96-Ig mediates strong CD8 CTL expansion in vivo. Am. J. Reprod. Immunol. 48: 220–225. 90. Srivastava, P. K., A. B. DeLeo, and L. J. Old. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. USA 83: 3407– 3411. 91. Udono, H., and P. K. Srivastava. 1994. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152: 5398–5403. 92. Udono, H., and P. K. Srivastava. 1993. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178: 1391–1396. 93. Basu, S., and P. K. Srivastava. 1999. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J. Exp. Med. 189: 797–802. 94. Wang, X. Y., L. Kazim, E. A. Repasky, and J. R. Subjeck. 2001. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 166: 490–497. 95. Eldor, R., S. Kassem, and I. Raz. 2009. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab. Res. Rev. 25: 316–320. 96. Birk, O. S., D. C. Douek, D. Elias, K. Takacs, H. Dewchand, S. L. Gur, M. D. Walker, R. van der Zee, I. R. Cohen, and D. M. Altmann. 1996. A role of Hsp60 in autoimmune diabetes: analysis in a transgenic model. Proc. Natl. Acad. Sci. USA 93: 1032–1037. 97. Chandawarkar, R. Y., M. S. Wagh, and P. K. Srivastava. 1999. The dual nature of specific immunological activity of tumor-derived gp96 preparations. J. Exp. Med. 189: 1437–1442. 98. Chandawarkar, R. Y., M. S. Wagh, J. T. Kovalchin, and P. Srivastava. 2004. Immune modulation with high-dose heat-shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int. Immunol. 16: 615–624. 99. Kovalchin, J. T., C. Mendonca, M. S. Wagh, R. Wang, and R. Y. Chandawarkar. 2006. In vivo treatment of mice with heat shock protein, gp 96, improves survival of skin grafts with minor and major antigenic disparity. Transpl. Immunol. 15: 179–185. 100. Tamura, Y., P. Peng, K. Liu, M. Daou, and P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278: 117–120. 101. Mo, A., C. Musselli, H. Chen, J. Pappas, K. Leclair, A. Liu, R. M. Chicz, A. Truneh, S. Monks, D. L. Levey, and P. K. Srivastava. 2011. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine 29: 8530–8541. 102. di Pietro, A., G. Tosti, P. F. Ferrucci, and A. Testori. 2011. The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. Expert Opin. Biol. Ther. 11: 1395–1407. 103. Raz, I., A. G. Ziegler, T. Linn, G. Schernthaner, F. Bonnici, L. A. Distiller, C. Giordano, F. Giorgino, L. de Vries, D. Mauricio, et al; DIA-AID 1 Writing Group. 2014. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care 37: 1392–1400. 104. Wald, A., D. M. Koelle, K. Fife, T. Warren, K. Leclair, R. M. Chicz, S. Monks, D. L. Levey, C. Musselli, and P. K. Srivastava. 2011. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 29: 8520–8529. 105. Liu, Z., X. Li, L. Qiu, X. Zhang, L. Chen, S. Cao, F. Wang, and S. Meng. 2009. Treg suppress CTL responses upon immunization with HSP gp96. Eur. J. Immunol. 39: 3110–3120.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
61. Basu, S., R. J. Binder, T. Ramalingam, and P. K. Srivastava. 2001. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14: 303–313. 62. Binder, R. J., and P. K. Srivastava. 2004. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc. Natl. Acad. Sci. USA 101: 6128–6133. 63. Binder, R. J. 2009. Hsp receptors: the cases of identity and mistaken identity. Curr. Opin. Mol. Ther. 11: 62–71. 64. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331: 1565–1570. 65. North, R. J., and D. P. Kirstein. 1977. T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites. J. Exp. Med. 145: 275– 292. 66. den Haan, J. M., and M. J. Bevan. 2001. Antigen presentation to CD8+ T cells: cross-priming in infectious diseases. Curr. Opin. Immunol. 13: 437–441. 67. Blanchard, T., P. K. Srivastava, and F. Duan. 2013. Vaccines against advanced melanoma. Clin. Dermatol. 31: 179–190. 68. Ma, Y., L. Aymeric, C. Locher, G. Kroemer, and L. Zitvogel. 2011. The dendritic cell-tumor cross-talk in cancer. Curr. Opin. Immunol. 23: 146–152. 69. Binder, R. J., and P. K. Srivastava. 2005. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol. 6: 593–599. 70. Li, M., G. M. Davey, R. M. Sutherland, C. Kurts, A. M. Lew, C. Hirst, F. R. Carbone, and W. R. Heath. 2001. Cell-associated ovalbumin is crosspresented much more efficiently than soluble ovalbumin in vivo. J. Immunol. 166: 6099–6103. 71. Kovacsovics-Bankowski, M., and K. L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267: 243–246. 72. Messmer, M. N., J. Pasmowitz, L. E. Kropp, S. C. Watkins, and R. J. Binder. 2013. Identification of the cellular sentinels for native immunogenic heat shock proteins in vivo. J. Immunol. 191: 4456–4465. 73. Suto, R., and P. K. Srivastava. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269: 1585–1588. 74. Blachere, N. E., Z. Li, R. Y. Chandawarkar, R. Suto, N. S. Jaikaria, S. Basu, H. Udono, and P. K. Srivastava. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186: 1315–1322. 75. Zhou, Y. J., M. N. Messmer, and R. J. Binder. 2014. Establishment of tumorassociated immunity requires interaction of heat shock proteins with CD91. Cancer Immunol. Res 2: 217–228. 76. Norbury, C. C., S. Basta, K. B. Donohue, D. C. Tscharke, M. F. Princiotta, P. Berglund, J. Gibbs, J. R. Bennink, and J. W. Yewdell. 2004. CD8+ T cell crosspriming via transfer of proteasome substrates. Science 304: 1318–1321. 77. Basu, S., R. J. Binder, R. Suto, K. M. Anderson, and P. K. Srivastava. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12: 1539–1546. 78. Pawaria, S., and R. J. Binder. 2011. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat. Commun. 2: 521. 79. Gallo, P. M., and S. Gallucci. 2013. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front. Immunol. 4: 138. 80. Li, W., D. Mu, F. Tian, Y. Hu, T. Jiang, Y. Han, J. Chen, G. Han, and X. Li. 2013. Exosomes derived from Rab27a-overexpressing tumor cells elicit efficient induction of antitumor immunity. Mol. Med. Rep. 8: 1876–1882. 81. Martin, C. A., S. E. Carsons, R. Kowalewski, D. Bernstein, M. Valentino, and F. Santiago-Schwarz. 2003. Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp)70 in the rheumatoid joint: possible mechanisms of hsp/DC-mediated cross-priming. J. Immunol. 171: 5736–5742. 82. Sedlackova, L., T. T. Nguyen, D. Zlacka, A. Sosna, and I. Hromadnikova. 2009. Cell surface and relative mRNA expression of heat shock protein 70 in human synovial cells. Autoimmunity 42: 17–24. 83. Huang, Q. Q., R. Sobkoviak, A. R. Jockheck-Clark, B. Shi, A. M. Mandelin, II, P. P. Tak, G. K. Haines, III, C. V. Nicchitta, and R. M. Pope. 2009. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. J. Immunol. 182: 4965–4973. 84. Auger, I., J. M. Escola, J. P. Gorvel, and J. Roudier. 1996. HLA-DR4 and HLADR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins. Nat. Med. 2: 306–310.
5771
References Subscriptions Permissions Email Alerts
Robert Julian Binder J Immunol 2014; 193:5765-5771; ; doi: 10.4049/jimmunol.1401417 http://www.jimmunol.org/content/193/12/5765
This article cites 105 articles, 53 of which you can access for free at: http://www.jimmunol.org/content/193/12/5765.full#ref-list-1 Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscriptions Submit copyright permission requests at: http://www.aai.org/ji/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/cgi/alerts/etoc
The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 9650 Rockville Pike, Bethesda, MD 20814-3994. Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
This information is current as of December 8, 2014.
Brief Reviews
The
Journal of
Immunology
Functions of Heat Shock Proteins in Pathways of the Innate and Adaptive Immune System Robert Julian Binder
H
eat shock proteins (HSPs) were inadvertently discovered in 1962 when Drosophila salivary glands were grown overnight at elevated temperatures and were found to be highly upregulated (1). Several HSPs have been discovered since then, and they are grouped into families based on m.w. (e.g., hsp10, hsp40, hsp60, hsp70, hsp90), although family members may be structurally unrelated (2). The ability of HSPs to chaperone nascent polypeptides for proper folding and expression is their best known function (2); however, a significant role for HSPs in the immune system has emerged in the past three decades and is the focus of this review. The usefulness of HSP-mediated immune responses for immunotherapy of disease is mentioned. The immunological roles for HSPs, in situ or in the extracellular environment, rely fully or partially on the fundamental property of a select few HSPs to act as a chaperone of peptides, in addition to whole proteins. Peptide-binding properties of select HSPs
The intracellular association of HSPs with peptides has been demonstrated on structural, biochemical, and immunological levels. The bacterial homolog of mammalian hsp70, DnaK, was crystallized in 1996, together with its associated peptide occupying a peptide-binding groove (3, 4). Peptide binding sites have been identified for calreticulin (5) and hsp90 (6), as well as its endoplasmic reticulum (ER) paralogue gp96 (7). Peptides associate with each of these HSPs with low affinity Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261 Received for publication June 3, 2014. Accepted for publication September 7, 2014. This work was supported by National Institutes of Health Grants CA90440, CA137133, and AI079057. Address correspondence and reprint requests to Dr. Robert Julian Binder, University of Pittsburgh School of Medicine, E1058 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15261. E-mail address: [email protected] www.jimmunol.org/cgi/doi/10.4049/jimmunol.1401417
and no or low specificity (8–10). The peptides are generally 10– 30 aa in length and are generated during normal protein turnover in cells (8–10). Because the peptide binding sites for each HSP are different, the case can be made for distinct associated peptide repertoires. It is important to note that the association of HSPs with peptides is not an artifact of cell lysis (11). In many immunological systems tested, peptides derived from antigenic proteins were shown to be associated with cytosolic (hsp90 and hsp70) and ER (calreticulin and gp96) HSPs. These antigenic peptides include those derived from viral (12–18) or bacterial (19) proteins from infected cells, tumor Ags from malignant cells (20–22), model Ags from transfected cells (23–27), and alloantigens from MHC-mismatched cells (28, 29). Immunologically, peptides chaperoned by HSPs reflect the antigenic fingerprint of a cell. Finally, the association of HSPs with peptides appears to be an evolutionarily conserved property, because HSPs from bacteria (3), amphibians (30), rodents (12–14, 17–19, 21–25, 31), and primates (16, 20) can bind peptides. The HSPs and MHC are the two prominent families of peptide-binding proteins in immunology. In situ HSPs and the immune system
HSPs and the MHC class I Ag-presentation pathway. The classical
view of the pathway that leads to productive peptide presentation by MHC class I (MHC I) begins with protein degradation by the cytosolic proteasome. Although the source of proteasome substrates is under intense debate (32, 33), extended polypeptides are cleaved to small peptides with the correct C-termini, but extended N-termini, for occupying MHC I. For several years these peptides were inexplicably assumed to diffuse from the proteasome to the TAP for transportation into the ER (34). ER peptides are loaded onto nascent MHC H chains with the assistance of the peptide loading complex (PLC) comprising TAP, tapasin, ERp57, and calreticulin. During loading onto MHC I, peptides simultaneously undergo a final round of N-terminal trimming by ER-associated protease (34). Peptide-loaded MHC I H chains associate with b2M, and the trimeric complex is transported through the Golgi and ultimately expressed on the cell surface, where it can be recognized by T cells. Studies from several laboratories argue strongly for Abbreviations used in this article: DC, dendritic cell; ER, endoplasmic reticulum; HSP, heat shock protein; MHC I, MHC class I; PLC, peptide-loading complex; RA, rheumatoid arthritis; Treg, regulatory T cell. Copyright Ó 2014 by The American Association of Immunologists, Inc. 0022-1767/14/$16.00
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
For more than 50 years, heat shock proteins (HSPs) have been studied for their role in protecting cells from elevated temperature and other forms of stress. More recently, several roles have been ascribed to HSPs in the immune system. These include intracellular roles in Ag presentation and expression of innate receptors, as well as extracellular roles in tumor immunosurveillance and autoimmunity. Exogenously administered HSPs can elicit a variety of immune responses that have been used in immunotherapy of cancer, infectious diseases, and autoimmune disease. The Journal of Immunology, 2014, 193: 5765–5771.
5766
resultant peptides can be presented by MHC I, a process referred to as cross-presentation (34). There is debate regarding the cellular compartment in which Ags are processed for cross-presentation (34, 50). Vesicular bodies into which Ag is internalized, such as endosomes or phagosomes, may become specialized peptide-processing and MHC I–loading compartments through recruitment of selective ER proteins that perform these roles. MHC I–peptide complexes in these vesicles recycle to the cell surface (50). A prevalent second pathway involves trans-endosomal membrane transport of the Ag to the cytosol where it enters the classical MHC I Ag-presentation pathway (34). In support of this, the proteasome dependence for cross-presentation of Ags by APCs was shown (34). hsp90 and hsp70 are intimately involved in the extrusion of Ags from the endosomes to the cytosol through a putative pore structure (51, 52). This mechanism involves the unfolding and linearization of the protein Ags by hsp90 prior to extrusion. Pharmacological inhibition of hsp90 or its deletion in cross-presenting APCs or Ag rendered structurally inflexible through fixation abrogated Ag cross-presentation (51). Interestingly, hsp70 was shown to negatively regulate Ag extrusion, arguing for cooperative regulation of this process by two cytosolic HSPs. These specific roles for hsp70 and hsp90 may account, at least in part, for the extraordinary efficiency of extracellular HSPs at cross-presenting Ags that are chaperoned by them (as described below). Endogenous HSPs, through functionality or expression levels, appear to be key regulators of Ag cross-presentation. Coincidentally, hsp90 and hsp70 are induced in response to stress and IFNs, the precise situations during which cross-presentation is required. gp96 as a chaperone of innate immune receptors. gp96 has a welldescribed function in the ER for folding nascent polypeptides into their final conformation (2). These client proteins are wholly dependent on gp96 for proper expression. All TLRs, with the exception of TLR3, are client proteins of gp96 (53). Folding of TLRs is dependent on dimerization of gp96 and its cochaperone CNPY3 also present in the ER lumen. Following gp96 depletion in APCs, TLRs are rapidly removed from the cell surface and intracellular vesicles, rendering APCs functionally unresponsive to corresponding TLR ligands, as measured by a lack of NF-kB activation and secretion of cytokines. Structural studies on gp96 identified the TLRbinding domains, which are distinct from ATP-binding domains (54). Several other client proteins, such as a and b integrins, known for their roles in influencing immune responses, bind to the same domain. Thus, mice deficient in gp96 expression are severely susceptible to bacterial infection (55). TLRs are the critical sensors for recognition of microorganisms, and their expression patterns are closely related to function. Upstream processes that determine TLR expression are expected to regulate immunity to pathogens; thus, gp96 is a master chaperone that can control immune responses with fine specificity based on selectivity and titratability in client binding. Extracellular HSPs and influence of adaptive immunity
Collectively, HSPs are the most abundant proteins in cells, and their liberation into the extracellular environment is a key immunological indicator of loss of cellular integrity. HSPs in the extracellular environment are a product of pathologic cell
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
modifications to this oversimplistic classical pathway. First, hydrophobic amino acids present in short peptides (which cannot assume higher-ordered structures) cannot exist in the aqueous intracellular environment without being shielded (35), a role provided by HSPs (Fig. 1). Second, diffusion as a transport mechanism is too uneconomical to satisfy the calculated efficiency of production of peptide/MHC I on the cell surface (36, 37). This efficient process can be satisfied by factoring in the HSPs. hsp70, hsp90, gp96, and calreticulin were proposed, in 1994, to form a relay line for efficient transport of peptides from the proteasome to MHC I (38). The following evidence strongly supports this proposal. 1) Disruption of peptide binding to hsp70 or hsp90 with deoxyspergualin or tanespimycin, respectively, abrogates peptide presentation by MHC I (39, 40). Knock down of hsp90a with small interfering RNA produces a similar phenotype (41). 2) When peptides are eluted from highly purified, apparently homogenous HSPs, MHC-binding peptides and their precursors (intermediates of the processing events) are found (8–10, 12–29). 3) Transfer of progressively trimmed peptides between HSPs and MHC I has been observed in the ER (42). 4) Naturally occurring free peptides cannot be detected in cells even after the most rigorous of experimental exploration (11). Once cells or their derived lysates are treated with ATP or mild acid, agents known to release peptides from chaperones, peptides can be readily detected (11). 5) Peptides transported by TAP associate with gp96 and other ER chaperones, including protein disulfide isomerase (43). These HSPs adhere to certain specifications to satisfactorily transfer peptides for MHC I presentation. The ubiquitous expression of hsp70, hsp90, calreticulin, and gp96 in cells essentially ensures that the MHC I–presentation pathway remains functional in all nucleated cells. IFN-g inducibility of a majority of the components of the MHC I–presentation pathway also applies to HSPs involved in the pathway (44, 45). The receipt and delivery of peptides by HSPs suggest a physical association of those HSPs with other components of the pathway. hsp90 was shown to physically associate with the proteasome and, in certain instances, replace the PA28 subunits (46, 47), situating hsp90 in an optimal position to receive peptides being generated by the proteasome. hsp70 and hsp90 form heteromultimeric complexes in the cytosol with other cochaperones (48). Although this complex is essential for client protein–refolding roles, peptide transfer within this complex has yet to be tested. hsp70 also were shown to be in physical proximity to TAP (49), an association that would allow delivery of HSP-chaperoned peptides to TAP for onward translocation into the ER. This suggests that the proteasomes, hsp70, hsp90, and TAP could exist as a single cytosolic multimeric unit akin to the PLC. Within the ER, the PLC has been well defined, with calreticulin playing a peptide-binding role. The transfer of peptides among calreticulin, gp96, and MHC I in the ER has been documented (42). The apparent lack of association of gp96 (and ERassociated protease) with other PLC members may reflect a weaker or transient interaction with this complex, considering the other significant roles for gp96 in ER biology. Other unidentified chaperones may be involved in this pathway. Cytosolic HSPs in endosome–cytosol trafficking of cross-presented Ags. APCs capture Ags from the extracellular space and internalize them into vesicular bodies. Following processing of the Ags,
BRIEF REVIEWS: HSPs IN THE IMMUNE SYSTEM
The Journal of Immunology
5767
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
FIGURE 1. (AA) hsp90 and hsp70 are intricately involved in shuttling peptides from the proteasome to TAP in the cytosol. In the ER, gp96 and calreticulin (CRT) sequentially transfer peptides from TAP to MHC. (AB) hsp90 and hsp70 regulate the extrusion of Ags from endosomes to the cytosol through a putative pore during Ag cross-presentation. (AC) gp96 folds and controls the expression of TLRs and other client proteins. HSPs released from tumor cells through a variety of mechanisms (BA) are endocytosed by CD91 expressed on APCs (BB). HSPs and the chaperoned peptides are processed within the cell (BC) before presentation of the peptide on MHC molecules to CD4 or CD8 T cells (BD). (BE) CD91 also serves as a signaling receptor, controlling the expression of cytokines and costimulatory molecules. (BF) Thus, HSPs can prime diverse Th cell responses.
5768
1) Tumor Ags have been grouped into neoantigens resulting from mutated, overexpressed, or abnormally expressed proteins (67), although the former are ubiquitous and appear to be the most immunogenic (67). Priming of tumor-specific T cells requires that these tumor Ags are transferred from the Ag-expressing (tumor) cell to APCs for cross-presentation (68). Mutated self proteins, expressed by a few abnormal cells, set the limitations for the amount of material available for cross-presentation during tumorigenesis. These limits have been quantified and are in the picogram range (69, 70). However, cross-presentation of soluble protein Ags, as measured in several model Ag and pathogen experimental systems, requires ∼10 to hundreds of micrograms [e.g., (66, 71)]. The five orders of disparity between these two quantities are satisfied when HSP– peptide complexes are considered as the mediators of Ag transfer (69). Peptides chaperoned by HSPs are efficiently cross-presented by APCs, and the efficiency is largely attributed to the presence of an endocytic receptor CD91 (60–62, 72). The mechanisms associated with cross-presentation of HSP-chaperoned peptides have been quantified and detailed in a large body of work (60–63, 73). Importantly, femtogram to picogram levels of a specific peptide complexed to 10 mg of gp96, hsp70, or calreticulin are sufficient for cross-presentation (74). My group proposed that the HSP–peptide–CD91
mode of Ag transfer must be used during tumorigenesis given limiting Ag levels. Mice deficient in CD91 expression on APCs failed to mount immune responses to growing tumors (75), a phenotype previously seen in IFN-g– or rag-deficient mice (64). CD91-deficient mice or tumors expressing endogenous inhibitors of CD91 fail to adequately cross-present Ag and stimulate T cell responses. These observations point to an indispensable role for endogenous tumor-derived HSPs and their receptor CD91 in establishing immune responses to a developing tumor. In other pathological situations in which Ag load is considerably higher, other modes of Ag transfer may apply (76). 2) Tumors, being of self origin, lack expression of pathogenassociated molecular patterns, which typically elicit costimulation. We do not know the origin of costimulation during tumorigenesis. Purified gp96, hsp70, and calreticulin were shown to stimulate and mature APCs, which are associated with cytokine release and upregulation of costimulatory molecules (77, 78). HSPstimulated dendritic cells (DCs) are perfectly suited for priming T cells. Incidentally, CD91 was shown to be a signaling receptor for immunogenic HSPs activating p38 MAPK and NF-kB (78). The repertoire of cytokines released and costimulatory molecules expressed are specific to the CD91+ APC and the HSP used, but routinely includes IL-1b, TNF-a, IL-6, IL12, and GM-CSF (78). HSP-stimulated APCs upregulate CD80, CD86, CD40, and MHC class II (77). In a tumor microenvironment, with the release of multiple HSPs and with APCs in this locale, the response is of the Th1 type, capable of rejecting the tumor. As a single entity, the HSP–peptide complexes are capable of priming T cell responses. These responses are considered in juxtaposition with other intracellular molecules capable of stimulating APCs, such as HMGB1, dsDNA, and uric acid (79). Cellular necrosis, which is a near-universal occurrence in cancer, appears to be the most rational mechanism for extracellular HSP release (56). However, there are other mechanisms through which HSPs are accessible to their receptor(s) on immune cells (57–59, 80). Therefore, immunologically dangerous situations can be classified quantitatively and qualitatively according to the potential for release of HSPs, or more generally, intracellular content, which provide signals that may complement, supersede, or antagonize those originating from other pathways (e.g., pathogen-associated molecular pattern–pattern recognition receptor) or, in the absence of other apparent signals, elicit exclusive responses. Extracellular HSPs and etiology of autoimmunity. During homeostasis, it is necessary that HSPs are largely inaccessible to their receptors. Sustained release of HSPs into the extracellular environment would be expected to trigger autoimmunity based on the observed proinflammatory conditions elicited by some HSPs. Although there is no formal experimental demonstration of this expectation, there is some suggestion of it in various pathological conditions.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
death, abnormal active secretory mechanisms, or nonconventional cellular expression on the membrane (56–59). A select group of HSPs, when extracellular, is recognized by cellular immune sentinels. Such recognition allows HSPs to be critical mediators of immune responses, initiating specific immune responses against cancers or pathogen-infected cells, exacerbating pre-existing inflammatory conditions, or suppressing ongoing immunity. The surprising discovery of HSP receptors on APCs afforded a molecular description of these immunological mechanisms (60–63) (Fig. 1B). Extracellular HSPs are necessary for immunosurveillance of cancer. The ability of the immune system to recognize aberrant, premalignant cells and eliminate them before they become pathological is the hallmark of tumor immunosurveillance (64). Immunosurveillance and resulting immunoediting include an elimination, equilibrium, and escape phase (64). T cell responses, initiated during the elimination phase, are primarily responsible for rejection of the tumorigenic cells (65). T cells receive signal 1 through TCR recognition of Ag presented by MHC. Recognition of costimulatory ligands on APCs by corresponding receptors on T cells provides signal 2. These signals are provided in the context of a cytokine milieu. In a majority of cases, these signals are sufficient for T cell priming, and all abnormal premalignant cells are eliminated. A failure of the immune system to completely eliminate the abnormal cells sets the stage for an equilibrium phase, a state that can persist for many years. Cancers then develop when they escape immune control. The conventional mechanism of priming T cells has been largely elucidated using experimental systems with model Ags or pathogens (66). These mechanisms are not wholly applicable during tumorigenesis and have been revised to include the immunological effects of HSPs for two reasons.
BRIEF REVIEWS: HSPs IN THE IMMUNE SYSTEM
The Journal of Immunology
hsp70 (see Ref. 102)], in patients with autoimmune diabetes [with hsp60 (95, 103)], and in virally infected patients [with hsp70 (104)]. The plasticity of HSP-mediated immunity (i.e., priming Th1, Th2, Th17, and/or Tregs) depends on the ability of HSPs to engage local APCs through cell surface receptors, thereby stimulating diverse costimulatory signals (77, 78, 95). CD91 is one such prominent receptor. When HSPs are introduced at higher doses, we speculate that additional APCs and/or (lower-affinity) cell surface receptors (63) could be targeted. The 24mer peptide of hsp60 offers a clear example: it was shown to bind TLR2 and TLR4 mediating anti- and proinflammatory conditions, respectively (95). The repertoires of cytokines released by bone marrow–derived dendritic cells, peritoneal exudate cells, and lymph node DCs stimulated with HSPs are overlapping, but distinct, and dependent on receptor usage (78). The overall signal received by the cell from engagement of multiple signaling receptors, as well as the resulting costimulation, determines the Th cell response that is primed. The recent demonstration that blocking Treg generation allowed gp96 to mediate stronger peptide-specific CTL responses in BALB/c mice provides further evidence for this dynamic interplay, as do the studies on hsp60 (95). Although many of the experimental systems are necessarily minimalistic, it is important to consider the sum of these signals during pathology in conjunction with signals emanating from other engaged (pattern recognition) receptors.
Conclusions
It has been 30 years since Srivastava and colleagues first described the immunogenicity of HSPs. The HSPs (and the receptor CD91) are evolutionarily ancient; thus, it is unsurprising that the immune system has evolved to use HSPs in conserved pathways. As we continue to better understand their functions, other roles for HSPs in innate and adaptive immunity may be uncovered, not only in the diseased state but also during homeostasis. With the recent appreciation of various commensals in regulating immune responses, for example, we are yet to appreciate the role of commensal-derived HSPs in generating signals that may affect those emanating from PRRs.
Acknowledgments I thank Drs. Abigail Sedlacek and Yu Jerry Zhou for advice and discussions.
Disclosures R.J.B. is a named inventor of intellectual property that is being evaluated under his National Institutes of Health grants, and the technology has been licensed to a company in which R.J.B. has no ownership interest or consulting contract and from which he has no sponsored research agreements. His significant financial interest consists only of a share of license fees and possible future royalties from the commercialization of his invention.
References 1. Ritossa, F. 1962. A new puffing pattern induced by temperature shock and DNP in drosophila. Experientia 18: 571–573. 2. Lindquist, S., and E. A. Craig. 1988. The heat-shock proteins. Annu. Rev. Genet. 22: 631–677. 3. Zhu, X., X. Zhao, W. F. Burkholder, A. Gragerov, C. M. Ogata, M. E. Gottesman, and W. A. Hendrickson. 1996. Structural analysis of substrate binding by the molecular chaperone DnaK. Science 272: 1606–1614. 4. Peng, P., A. Me´noret, and P. K. Srivastava. 1997. Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. J. Immunol. Methods 204: 13–21.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
The etiology of rheumatoid arthritis (RA) remains largely unresolved and is likely to be a combination of genetic, environmental, and immunological factors. However, a case can be made for extracellular HSPs as a factor contributing to the initiation and/or progression of RA. Elevated levels of hsp70 and gp96 are observed in synovial fluids and fibroblasts from inflamed joints of RA patients (81–83). This increase is not observed in nonarthritic joints of the same patient. Macrophages lining the synovial tissue of RA joints are highly responsive to extracellular HSPs and produce cytokines, including IL-1b, IL-6, and TNF-a, which exacerbate the inflammatory conditions (83). Already, therapy targeting HSPs with Abs is being envisaged. A therapeutic focus on the upstream molecules that initiate inflammation is expected to be more successful than the current anti–TNF-a therapy. A majority of the peptides chaperoned by HSPs are self peptides. In the event that autoreactive T cells are not thymically deleted, they can be primed following HSP-mediated crosspresentation of these self peptides (84), further contributing to cellular destruction of arthritic joints. In some other instances, these self peptides may even be derived from the HSP molecule itself and, thus, are a target for cellular immunity or are able to induce protective immunity (85–87). In experimental systems, transgenic mice with enforced cell surface expression of gp96 develop spontaneous lupus-like autoimmune disease as a result of chronic stimulation of DCs (88). Although there were no apparent gross abnormalities, these mice displayed severe glomerulonephritis by 20 wk of age. DCs in these mice were found to be hyperactive and capable of priming self-reactive T cells, and of breaking down peripheral tolerance. These studies were able to demonstrate the direct proinflammatory properties of constitutive extracellular gp96 in mice, a condition similar to immunization with tumor cells secreting HSPs (89). Exogenously administered HSPs and modulation of immune responses. Immunogenicity of HSPs was first shown in 1986 during a search of the immunogenic entity of tumor cells (90). Srivastava et al. biochemically fractionated tumor cells and tested each fraction for its ability to elicit tumor rejection in mice. Apparently homogenous preparations of gp96 were shown to do so. Thus, when mice are immunized with gp96 isolated from a tumor, they become resistant to a subsequent challenge of that specific tumor. The specificity of the immune responses was against peptides chaperoned by gp96. These observations are true for other peptide-chaperoning HSPs, including hsp70 (91, 92), hsp90 (91), calreticulin (93), hsp110 (94), and grp170 (94), and are effective in many disease models in rodents (90–94), frogs (30), and humans (see below). Following on those pioneering studies, depending on the dose and experimental setting, HSPs were shown to prime not only specific antitumor immunity (90–94), but also regulatory T cell (Treg) responses [hsp70 (85), hsp60 (95, 96), gp96 (97–99)], Ab responses [hsp60 (95), gp96 (13)], or Th17 responses (78) (calreticulin, gp96). The natural extension of these observations was therapeutic experimentation in various diseases. First, in rodent models, HSPs were shown to regress established tumors and prevent metastasis [gp96 (100), hsp70 (100), hsp110 (94), grp170 (94)], prevent or delay autoimmunity [hsp60 (95), gp96 (97–99)], and reduce pathogen load [gp96 (13, 18, 101)]. There is an extensive list of clinical trials in patients with a variety of cancers [with gp96,
5769
5770
32. Yewdell, J. W., and C. V. Nicchitta. 2006. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol. 27: 368–373. 33. Rock, K. L., D. J. Farfa´n-Arribas, J. D. Colbert, and A. L. Goldberg. 2014. Reexamining class-I presentation and the DRiP hypothesis. Trends Immunol. 35: 144–152. 34. Blum, J. S., P. A. Wearsch, and P. Cresswell. 2013. Pathways of antigen processing. Annu. Rev. Immunol. 31: 443–473. 35. Dick, T. P., T. Ruppert, M. Groettrup, P. M. Kloetzel, L. Kuehn, U. H. Koszinowski, S. Stevanovic´, H. Schild, and H. G. Rammensee. 1996. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86: 253–262. 36. Villanueva, M. S., P. Fischer, K. Feen, and E. G. Pamer. 1994. Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity 1: 479–489. 37. Yewdell, J. W., E. Reits, and J. Neefjes. 2003. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3: 952–961. 38. Srivastava, P. K., H. Udono, N. E. Blachere, and Z. Li. 1994. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39: 93–98. 39. Binder, R. J., N. E. Blachere, and P. K. Srivastava. 2001. Heat shock proteinchaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J. Biol. Chem. 276: 17163–17171. 40. Callahan, M. K., M. Garg, and P. K. Srivastava. 2008. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proc. Natl. Acad. Sci. USA 105: 1662–1667. 41. Kunisawa, J., and N. Shastri. 2006. Hsp90alpha chaperones large C-terminally extended proteolytic intermediates in the MHC class I antigen processing pathway. Immunity 24: 523–534. 42. Kropp, L. E., M. Garg, and R. J. Binder. 2010. Ovalbumin-derived precursor peptides are transferred sequentially from gp96 and calreticulin to MHC class I in the endoplasmic reticulum. J. Immunol. 184: 5619–5627. 43. Spee, P., and J. Neefjes. 1997. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur. J. Immunol. 27: 2441–2449. 44. Anderson, S. L., T. Shen, J. Lou, L. Xing, N. E. Blachere, P. K. Srivastava, and B. Y. Rubin. 1994. The endoplasmic reticular heat shock protein gp96 is transcriptionally upregulated in interferon-treated cells. J. Exp. Med. 180: 1565–1569. 45. Wang, S., M. Zhou, F. Lin, D. Liu, W. Hong, L. Lu, Y. Zhu, and A. Xu. 2014. Interferon-g induces senescence in normal human melanocytes. PLoS ONE 9: e93232. 46. Yamano, T., S. Mizukami, S. Murata, T. Chiba, K. Tanaka, and H. Udono. 2008. Hsp90-mediated assembly of the 26 S proteasome is involved in major histocompatibility complex class I antigen processing. J. Biol. Chem. 283: 28060– 28065. 47. Yamano, T., S. Murata, N. Shimbara, N. Tanaka, T. Chiba, K. Tanaka, K. Yui, and H. Udono. 2002. Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing. J. Exp. Med. 196: 185–196. 48. French, J. B., H. Zhao, S. An, S. Niessen, Y. Deng, B. F. Cravatt, and S. J. Benkovic. 2013. Hsp70/Hsp90 chaperone machinery is involved in the assembly of the purinosome. Proc. Natl. Acad. Sci. USA 110: 2528–2533. 49. Chen, D., and M. J. Androlewicz. 2001. Heat shock protein 70 moderately enhances peptide binding and transport by the transporter associated with antigen processing. Immunol. Lett. 75: 143–148. 50. Jutras, I., and M. Desjardins. 2005. Phagocytosis: at the crossroads of innate and adaptive immunity. Annu. Rev. Cell Dev. Biol. 21: 511–527. 51. Ichiyanagi, T., T. Imai, C. Kajiwara, S. Mizukami, A. Nakai, T. Nakayama, and H. Udono. 2010. Essential role of endogenous heat shock protein 90 of dendritic cells in antigen cross-presentation. J. Immunol. 185: 2693–2700. 52. Imai, T., Y. Kato, C. Kajiwara, S. Mizukami, I. Ishige, T. Ichiyanagi, M. Hikida, J. Y. Wang, and H. Udono. 2011. Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells. Proc. Natl. Acad. Sci. USA 108: 16363–16368. 53. Liu, B., Y. Yang, Z. Qiu, M. Staron, F. Hong, Y. Li, S. Wu, Y. Li, B. Hao, R. Bona, et al. 2010. Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone. Nat. Commun. 1: 79. 54. Wu, S., F. Hong, D. Gewirth, B. Guo, B. Liu, and Z. Li. 2012. The molecular chaperone gp96/GRP94 interacts with Toll-like receptors and integrins via its Cterminal hydrophobic domain. J. Biol. Chem. 287: 6735–6742. 55. Staron, M., Y. Yang, B. Liu, J. Li, Y. Shen, J. C. Zu´n˜iga-Pfl€ ucker, H. L. Aguila, I. Goldschneider, and Z. Li. 2010. gp96, an endoplasmic reticulum master chaperone for integrins and Toll-like receptors, selectively regulates early T and B lymphopoiesis. Blood 115: 2380–2390. 56. Miyake, Y., and S. Yamasaki. 2012. Sensing necrotic cells. Adv. Exp. Med. Biol. 738: 144–152. 57. Hunter, M. C., K. L. O’Hagan, A. Kenyon, K. C. Dhanani, E. Prinsloo, and A. L. Edkins. 2014. Hsp90 binds directly to fibronectin (FN) and inhibition reduces the extracellular fibronectin matrix in breast cancer cells. PLoS ONE 9: e86842. 58. Altmeyer, A., R. G. Maki, A. M. Feldweg, M. Heike, V. P. Protopopov, S. K. Masur, and P. K. Srivastava. 1996. Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. Int. J. Cancer 69: 340–349. 59. Becker, B., G. Multhoff, B. Farkas, P. J. Wild, M. Landthaler, W. Stolz, and T. Vogt. 2004. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp. Dermatol. 13: 27–32. 60. Binder, R. J., D. K. Han, and P. K. Srivastava. 2000. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1: 151–155.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
5. Chouquet, A., H. Paı¨dassi, W. L. Ling, P. Frachet, G. Houen, G. J. Arlaud, and C. Gaboriaud. 2011. X-ray structure of the human calreticulin globular domain reveals a peptide-binding area and suggests a multi-molecular mechanism. PLoS ONE 6: e17886. 6. Stirling, P. C., S. F. Bakhoum, A. B. Feigl, and M. R. Leroux. 2006. Convergent evolution of clamp-like binding sites in diverse chaperones. Nat. Struct. Mol. Biol. 13: 865–870. 7. Ostrovsky, O., C. A. Makarewich, E. L. Snapp, and Y. Argon. 2009. An essential role for ATP binding and hydrolysis in the chaperone activity of GRP94 in cells. Proc. Natl. Acad. Sci. USA 106: 11600–11605. 8. Grossmann, M. E., B. J. Madden, F. Gao, Y. P. Pang, J. E. Carpenter, D. McCormick, and C. Y. Young. 2004. Proteomics shows Hsp70 does not bind peptide sequences indiscriminately in vivo. Exp. Cell Res. 297: 108–117. 9. Demine, R., and P. Walden. 2005. Testing the role of gp96 as peptide chaperone in antigen processing. J. Biol. Chem. 280: 17573–17578. 10. Li, H. Z., C. W. Li, C. Y. Li, B. F. Zhang, L. T. Li, J. M. Li, J. N. Zheng, and J. W. Chang. 2013. Isolation and identification of renal cell carcinoma-derived peptides associated with GP96. Technol. Cancer Res. Treat. 12: 285–293. 11. Me´noret, A., P. Peng, and P. K. Srivastava. 1999. Association of peptides with heat shock protein gp96 occurs in vivo and not after cell lysis. Biochem. Biophys. Res. Commun. 262: 813–818. 12. Nieland, T. J., M. C. Tan, M. Monne-van Muijen, F. Koning, A. M. Kruisbeek, and G. M. van Bleek. 1996. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc. Natl. Acad. Sci. USA 93: 6135–6139. 13. Navaratnam, M., M. S. Deshpande, M. J. Hariharan, D. S. Zatechka, Jr., and S. Srikumaran. 2001. Heat shock protein-peptide complexes elicit cytotoxic Tlymphocyte and antibody responses specific for bovine herpesvirus 1. Vaccine 19: 1425–1434. 14. Meng, S. D., T. Gao, G. F. Gao, and P. Tien. 2001. HBV-specific peptide associated with heat-shock protein gp96. Lancet 357: 528–529. 15. Heikema, A., E. Agsteribbe, J. Wilschut, and A. Huckriede. 1997. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol. Lett. 57: 69–74. 16. Strbo, N., M. Vaccari, S. Pahwa, M. A. Kolber, M. N. Doster, E. Fisher, L. Gonzalez, D. Stablein, G. Franchini, and E. R. Podack. 2013. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J. Immunol. 190: 2495–2499. 17. Basta, S., R. Stoessel, M. Basler, M. van den Broek, and M. Groettrup. 2005. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J. Immunol. 175: 796–805. 18. Z€ ugel, U., A. M. Sponaas, J. Neckermann, B. Schoel, and S. H. Kaufmann. 2001. gp96-peptide vaccination of mice against intracellular bacteria. Infect. Immun. 69: 4164–4167. 19. Rapp, U. K., and S. H. Kaufmann. 2004. DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int. Immunol. 16: 597–605. 20. Castelli, C., A. M. Ciupitu, F. Rini, L. Rivoltini, A. Mazzocchi, R. Kiessling, and G. Parmiani. 2001. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 61: 222–227. 21. Ishii, T., H. Udono, T. Yamano, H. Ohta, A. Uenaka, T. Ono, A. Hizuta, N. Tanaka, P. K. Srivastava, and E. Nakayama. 1999. Isolation of MHC class Irestricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J. Immunol. 162: 1303–1309. 22. Qian, J., S. Wang, J. Yang, J. Xie, P. Lin, M. E. Freeman, III, and Q. Yi. 2005. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin. Cancer Res. 11: 8808–8815. 23. Breloer, M., T. Marti, B. Fleischer, and A. von Bonin. 1998. Isolation of processed, H-2Kb-binding ovalbumin-derived peptides associated with the stress proteins HSP70 and gp96. Eur. J. Immunol. 28: 1016–1021. 24. Arnold, D., C. Wahl, S. Faath, H.-G. Rammensee, and H. Schild. 1997. Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein gp96. J. Exp. Med. 186: 461–466. 25. Binder, R. J., J. B. Kelly, III, R. E. Vatner, and P. K. Srivastava. 2007. Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins. J. Immunol. 179: 7254–7261. 26. Dai, J., B. Liu, M. M. Caudill, H. Zheng, Y. Qiao, E. R. Podack, and Z. Li. 2003. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immun. 3: 1. 27. Nair, S., P. A. Wearsch, D. A. Mitchell, J. J. Wassenberg, E. Gilboa, and C. V. Nicchitta. 1999. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J. Immunol. 162: 6426–6432. 28. Arnold, D., S. Faath, H. Rammensee, and H. Schild. 1995. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182: 885–889. 29. Lammert, E., D. Arnold, H. G. Rammensee, and H. Schild. 1996. Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation. Eur. J. Immunol. 26: 875–879. 30. Robert, J., T. Ramanayake, G. D. Maniero, H. Morales, and A. S. Chida. 2008. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J. Immunol. 180: 3176–3182. 31. Yedavelli, S. P., L. Guo, M. E. Daou, P. K. Srivastava, A. Mittelman, and R. K. Tiwari. 1999. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int. J. Mol. Med. 4: 243–248.
BRIEF REVIEWS: HSPs IN THE IMMUNE SYSTEM
The Journal of Immunology
85. van Herwijnen, M. J., L. Wieten, R. van der Zee, P. J. van Kooten, J. P. WagenaarHilbers, A. Hoek, I. den Braber, S. M. Anderton, M. Singh, H. D. Meiring, et al. 2012. Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis. Proc. Natl. Acad. Sci. USA 109: 14134–14139. 86. Massa, M., M. Passalia, S. M. Manzoni, R. Campanelli, L. Ciardelli, G. P. Yung, S. Kamphuis, A. Pistorio, V. Meli, A. Sette, et al. 2007. Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum. 56: 1648–1657. 87. Aalberse, J. A., B. J. Prakken, and B. Kapitein. 2012. HSP: Bystander Antigen in Atopic Diseases? Front. Immunol. 3: 139–144. 88. Liu, B., J. Dai, H. Zheng, D. Stoilova, S. Sun, and Z. Li. 2003. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc. Natl. Acad. Sci. USA 100: 15824–15829. 89. Strbo, N., K. Yamazaki, K. Lee, D. Rukavina, and E. R. Podack. 2002. Heat shock fusion protein gp96-Ig mediates strong CD8 CTL expansion in vivo. Am. J. Reprod. Immunol. 48: 220–225. 90. Srivastava, P. K., A. B. DeLeo, and L. J. Old. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. USA 83: 3407– 3411. 91. Udono, H., and P. K. Srivastava. 1994. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152: 5398–5403. 92. Udono, H., and P. K. Srivastava. 1993. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178: 1391–1396. 93. Basu, S., and P. K. Srivastava. 1999. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J. Exp. Med. 189: 797–802. 94. Wang, X. Y., L. Kazim, E. A. Repasky, and J. R. Subjeck. 2001. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 166: 490–497. 95. Eldor, R., S. Kassem, and I. Raz. 2009. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab. Res. Rev. 25: 316–320. 96. Birk, O. S., D. C. Douek, D. Elias, K. Takacs, H. Dewchand, S. L. Gur, M. D. Walker, R. van der Zee, I. R. Cohen, and D. M. Altmann. 1996. A role of Hsp60 in autoimmune diabetes: analysis in a transgenic model. Proc. Natl. Acad. Sci. USA 93: 1032–1037. 97. Chandawarkar, R. Y., M. S. Wagh, and P. K. Srivastava. 1999. The dual nature of specific immunological activity of tumor-derived gp96 preparations. J. Exp. Med. 189: 1437–1442. 98. Chandawarkar, R. Y., M. S. Wagh, J. T. Kovalchin, and P. Srivastava. 2004. Immune modulation with high-dose heat-shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int. Immunol. 16: 615–624. 99. Kovalchin, J. T., C. Mendonca, M. S. Wagh, R. Wang, and R. Y. Chandawarkar. 2006. In vivo treatment of mice with heat shock protein, gp 96, improves survival of skin grafts with minor and major antigenic disparity. Transpl. Immunol. 15: 179–185. 100. Tamura, Y., P. Peng, K. Liu, M. Daou, and P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278: 117–120. 101. Mo, A., C. Musselli, H. Chen, J. Pappas, K. Leclair, A. Liu, R. M. Chicz, A. Truneh, S. Monks, D. L. Levey, and P. K. Srivastava. 2011. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine 29: 8530–8541. 102. di Pietro, A., G. Tosti, P. F. Ferrucci, and A. Testori. 2011. The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. Expert Opin. Biol. Ther. 11: 1395–1407. 103. Raz, I., A. G. Ziegler, T. Linn, G. Schernthaner, F. Bonnici, L. A. Distiller, C. Giordano, F. Giorgino, L. de Vries, D. Mauricio, et al; DIA-AID 1 Writing Group. 2014. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care 37: 1392–1400. 104. Wald, A., D. M. Koelle, K. Fife, T. Warren, K. Leclair, R. M. Chicz, S. Monks, D. L. Levey, C. Musselli, and P. K. Srivastava. 2011. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 29: 8520–8529. 105. Liu, Z., X. Li, L. Qiu, X. Zhang, L. Chen, S. Cao, F. Wang, and S. Meng. 2009. Treg suppress CTL responses upon immunization with HSP gp96. Eur. J. Immunol. 39: 3110–3120.
Downloaded from http://www.jimmunol.org/ at University of California San Francisco on December 8, 2014
61. Basu, S., R. J. Binder, T. Ramalingam, and P. K. Srivastava. 2001. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14: 303–313. 62. Binder, R. J., and P. K. Srivastava. 2004. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc. Natl. Acad. Sci. USA 101: 6128–6133. 63. Binder, R. J. 2009. Hsp receptors: the cases of identity and mistaken identity. Curr. Opin. Mol. Ther. 11: 62–71. 64. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331: 1565–1570. 65. North, R. J., and D. P. Kirstein. 1977. T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites. J. Exp. Med. 145: 275– 292. 66. den Haan, J. M., and M. J. Bevan. 2001. Antigen presentation to CD8+ T cells: cross-priming in infectious diseases. Curr. Opin. Immunol. 13: 437–441. 67. Blanchard, T., P. K. Srivastava, and F. Duan. 2013. Vaccines against advanced melanoma. Clin. Dermatol. 31: 179–190. 68. Ma, Y., L. Aymeric, C. Locher, G. Kroemer, and L. Zitvogel. 2011. The dendritic cell-tumor cross-talk in cancer. Curr. Opin. Immunol. 23: 146–152. 69. Binder, R. J., and P. K. Srivastava. 2005. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol. 6: 593–599. 70. Li, M., G. M. Davey, R. M. Sutherland, C. Kurts, A. M. Lew, C. Hirst, F. R. Carbone, and W. R. Heath. 2001. Cell-associated ovalbumin is crosspresented much more efficiently than soluble ovalbumin in vivo. J. Immunol. 166: 6099–6103. 71. Kovacsovics-Bankowski, M., and K. L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267: 243–246. 72. Messmer, M. N., J. Pasmowitz, L. E. Kropp, S. C. Watkins, and R. J. Binder. 2013. Identification of the cellular sentinels for native immunogenic heat shock proteins in vivo. J. Immunol. 191: 4456–4465. 73. Suto, R., and P. K. Srivastava. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269: 1585–1588. 74. Blachere, N. E., Z. Li, R. Y. Chandawarkar, R. Suto, N. S. Jaikaria, S. Basu, H. Udono, and P. K. Srivastava. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186: 1315–1322. 75. Zhou, Y. J., M. N. Messmer, and R. J. Binder. 2014. Establishment of tumorassociated immunity requires interaction of heat shock proteins with CD91. Cancer Immunol. Res 2: 217–228. 76. Norbury, C. C., S. Basta, K. B. Donohue, D. C. Tscharke, M. F. Princiotta, P. Berglund, J. Gibbs, J. R. Bennink, and J. W. Yewdell. 2004. CD8+ T cell crosspriming via transfer of proteasome substrates. Science 304: 1318–1321. 77. Basu, S., R. J. Binder, R. Suto, K. M. Anderson, and P. K. Srivastava. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12: 1539–1546. 78. Pawaria, S., and R. J. Binder. 2011. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat. Commun. 2: 521. 79. Gallo, P. M., and S. Gallucci. 2013. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front. Immunol. 4: 138. 80. Li, W., D. Mu, F. Tian, Y. Hu, T. Jiang, Y. Han, J. Chen, G. Han, and X. Li. 2013. Exosomes derived from Rab27a-overexpressing tumor cells elicit efficient induction of antitumor immunity. Mol. Med. Rep. 8: 1876–1882. 81. Martin, C. A., S. E. Carsons, R. Kowalewski, D. Bernstein, M. Valentino, and F. Santiago-Schwarz. 2003. Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp)70 in the rheumatoid joint: possible mechanisms of hsp/DC-mediated cross-priming. J. Immunol. 171: 5736–5742. 82. Sedlackova, L., T. T. Nguyen, D. Zlacka, A. Sosna, and I. Hromadnikova. 2009. Cell surface and relative mRNA expression of heat shock protein 70 in human synovial cells. Autoimmunity 42: 17–24. 83. Huang, Q. Q., R. Sobkoviak, A. R. Jockheck-Clark, B. Shi, A. M. Mandelin, II, P. P. Tak, G. K. Haines, III, C. V. Nicchitta, and R. M. Pope. 2009. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. J. Immunol. 182: 4965–4973. 84. Auger, I., J. M. Escola, J. P. Gorvel, and J. Roudier. 1996. HLA-DR4 and HLADR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins. Nat. Med. 2: 306–310.
5771
